To see the other types of publications on this topic, follow the link: Quality of life of patients with bronchial asthma.
Journal articles on the topic 'Quality of life of patients with bronchial asthma'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Quality of life of patients with bronchial asthma.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Alikulova, Dilrabo, and Rixsi Salikhodjaeva. "EVALUATION OF QUALITY OF LIFE OF PATIENTS WITH PRIMARY BRONCHIAL ASTHMA IN THE HEALTH CARE SYSTEM." UZBEK MEDICAL JOURNAL 2, no. 4 (April 30, 2021): 51–54. http://dx.doi.org/10.26739/2181-0664-2021-4-8.
Full textAbstract:
The study of risk factors leading to the development of asthma, conducted in the form of a survey and interviews. 52% of patients with a diagnosis of asthma noted the presence of the disease among close relatives. Among the risk factors leading to bronchial asthma, the most common are pollen and tobacco (49.1%). 59.2% of patients diagnosed with asthma do not follow the diet. Keywords:asthma, nurses, primary health care, prevention, risk factors
2
Timoshina, Ye L., and S. B. Dugarova. "Quality of life: actual of problem and characteristics quality of life children with bronchial asthma." Bulletin of Siberian Medicine 8, no. 4 (August 28, 2009): 105–11. http://dx.doi.org/10.20538/1682-0363-2009-4-105-111.
Full text
3
Nalina, N., M. Chandra, and Umashankar. "Assessment of quality of life in bronchial asthma patients." International Journal of Medicine and Public Health 5, no. 1 (2015): 93. http://dx.doi.org/10.4103/2230-8598.151270.
Full text
4
Poliak, A., T. Vastchenko, V. Moiseenko, and K. Sulima. "New quality of life in patients with bronchial asthma." Patient Education and Counseling 23 (June 1994): S58. http://dx.doi.org/10.1016/0738-3991(94)90233-x.
Full text
5
Smetanenko, T. V., and O. S. Kobyakova. "Quality of life in patients having severe bronchial asthma." Bulletin of Siberian Medicine 4, no. 4 (December 30, 2005): 71–77. http://dx.doi.org/10.20538/1682-0363-2005-4-71-77.
Full text
6
Fassakhov, R. S. "Successful management of severe bronchial asthma: the right choice of biologic therapy in properly selected patients." Medical Council, no. 15 (December 8, 2019): 22–28. http://dx.doi.org/10.21518/2079-701x-2019-15-22-28.
Full textAbstract:
Severe asthma along with the impact on the quality of life of those suffering from this disease leads to significant medical and social damage. Studies of the last decade indicate the leading role of eosinophilic inflammation of the bronchi as the basis of the pathogenesis of the T2 phenotype of bronchial asthma, which led to the development of targeted therapy. The most effective in this direction were preparations of humanized monoclonal antibodies directed against the main pro-inflammatory cytokines involved in respiratory tract inflammation in bronchial asthma, one of the most significant among which is interleukin 5. Refinement of the definition of severe asthma, selection of these patients among patients with difficult to treat bronchial asthma allows to clearly determine the contingent with a predicted positive effect these highly effective drugs precision therapy. On clinical examples, the difference between difficult to treat and severe bronchial asthma is discussed. The stages of clinical trials of the preparation of monoclonal antibodies against interleukin 5 Mepolizumab are analyzed in detail, the search for effective prognostic biological markers available in normal practice, allowing to select patients suitable for the treatment of patients with severe eosinophilic bronchial asthma. The effectiveness of the approach based on the allocation of two threshold values of the number of eosinophils in the peripheral blood is convincingly confirmed by the results indicating a significant reduction in the number of exacerbations, improved of lung function and an increase of the quality of life in patients, including with steroiddependent bronchial asthma, obtained not only in randomized clinical studies, but also in studies in real clinical practice.
7
Andreeva, G. F., M. I. Smirnova, V. M. Gorbunov, A. S. Kurekhyan, and Ya N. Koshelyaevskaya. "Seasonal Indicators of Blood Pressure, Data of Asthma Control Questionnaires and Quality of Life in Hypertensive Patients with Bronchial Asthma." Rational Pharmacotherapy in Cardiology 15, no. 6 (January 3, 2020): 831–39. http://dx.doi.org/10.20996/1819-6446-2019-15-6-831-839.
Full textAbstract:
Aim. To study the seasonal indicators of quality of life and control of bronchial asthma in hypertensive patients with bronchial asthma, observed by a cardiologist of the state outpatient institution.Material and methods. Data from a prospective cohort study of hypertensive patients, some of which had bronchial asthma without exacerbation, were analyzed. Patients who were observed by a cardiologist at a state outpatient clinic took part in the study. There were other concomitant diseases that occurred in the participants, in addition to hypertension and bronchial asthma. Two groups of patients were formed: the control group (n=85) included patients with hypertension only, the main group (n=40) included hypertension and bronchial asthma. Patients had 3 visits: initial one, and after 6 and 12 months and then data on outcomes (30.1Ѓ}7.6 months of follow-up) were collected. The first and third visits included clinical measurements of blood pressure (BP), 24-hour BP monitoring, spirometry, clinical and biochemical blood tests, a standard survey, survey with questionnaires evaluating the control of bronchial asthma (Asthma Control Questionnaire; ACQ) and the patients quality of life (General Well-Being Questionnaire; GWBQ). The second visit included clinical BP and ACQ and GWBQ questionnaires. A comparison of the average indicators from the total number of observations carried out in winter, spring, summer and autumn periods has been performed.Results. Hypertensive patients with/without bronchial asthma (n=125; 28 men, 97 women, average age 62.6Ѓ}8.8 years, duration of hypertension – 11.6Ѓ}8.6, duration of bronchial asthma – 9.3Ѓ}11.9 years) took part in the study. Outpatient BP levels throughout the study period were maintained at target values in both groups. It was shown that seasonal BP levels do not differ in the compared groups, except for winter indicators: winter daytime systolic BP levels were higher in the main group (p=0.03). Seasonal fluctuations in BP were not detected in the control group, however, they were present in the patients of the main group: winter daytime levels of diastolic BP and average daily levels of diastolic BP and systolic BP were higher than summer ones, and winter daytime systolic BP values (p<0.05) and clinical diastolic BP (p=0.004) – higher than autumn levels. Seasonal quality of life indicators in the main group were worse than in the control group in all seasons. Significant seasonal dynamics of quality of life indicators in patients in two groups was not detected. The ACQ questionnaire showed that asthma control changed in different seasons in accordance with the ACQ total score: in winter and spring – uncontrolled bronchial asthma (total score >1.5), in summer and autumn – partially controlled (total score ≤1.5). During the analysis of various factors associated with the combined primary endpoint (death, transient ischemic attack, angina pectoris, cardiac arrhythmias, arterial revascularization), relationships with quality of life indicators were revealed: negative connections – with indicators characterizing positive psychological health, mood at visit, positive correlations – with psychological abilities.Conclusion: Seasonal fluctuations in ambulatory BP levels were not found in the control group and were found in the main group. The quality of life indicators for patients of the main group were significantly worse than in the control group for all components in all seasons. The control of asthma changed in different seasons in accordance with the ACQ total score: uncontrolled bronchial asthma occurred in winter and spring, partially controlled – in summer and autumn. Correlations of the combined primary endpoint with quality of life indicators were found after analyzing various factors.
8
Faye, A. D., S. Gawande, R. Tadke, V. C. Kirpekar, S. H. Bhave, A. P. Pakhare, and B. Tayade. "Do Panic Symptoms Affect the Quality of Life and Add to the Disability in Patients with Bronchial Asthma?" Psychiatry Journal 2015 (2015): 1–8. http://dx.doi.org/10.1155/2015/608351.
Full textAbstract:
Background. Anxiety and panic are known to be associated with bronchial asthma with variety of impact on clinical presentation, treatment outcome, comorbidities, quality of life, and functional disability in patients with asthma. This study aims to explore the pattern of panic symptoms, prevalence and severity of panic disorder (PD), quality of life, and disability in them.Methods. Sixty consecutive patients of bronchial asthma were interviewed using semistructured proforma, Panic and Agoraphobia scale, WHO Quality of life (QOL) BREF scale, and WHO disability schedule II (WHODAS II).Results. Though 60% of the participants had panic symptoms, only 46.7% had diagnosable panic attacks according to DSM IV TR diagnostic criteria and 33.3% had PD. Most common symptoms were “sensations of shortness of breath or smothering,” “feeling of choking,” and “fear of dying” found in 83.3% of the participants. 73.3% of the participants had poor quality of life which was most impaired in physical and environmental domains. 55% of the participants had disability score more than a mean (18.1).Conclusion. One-third of the participants had panic disorder with significant effect on physical and environmental domains of quality of life. Patients with more severe PD and bronchial asthma had more disability.
9
Zaikina, Yulia, Nataliia Cherednichenko, Hanna Tymchenko, Gennadii Kochuiev, and Maryna Kochuieva. "Evaluation of the obesity influence on the life quality in patients with bronchial asthma." EUREKA: Health Sciences, no. 3 (May 25, 2021): 31–36. http://dx.doi.org/10.21303/2504-5679.2021.001842.
Full textAbstract:
The obese asthma is characterized by a more severe course. The feature of this comorbid condition is the reduced effectiveness of basic therapy with inhaled corticosteroids, which prevents optimal control of symptoms, requires increasing doses and increases the number of exacerbations and hospitalizations. The problem of life quality (LQ) research in patients with asthma and obesity is highly relevant today, which made it the reason for this study.
The aim of the study was to determine the effect of obesity on LQ in patients with asthma.
Materials and methods. We selected for participating in the study 46 patients with moderate severity asthma. Examination of the patients included: objective examination with an anthropometric evaluation, the test of the LQ with two questionnaires: general one – Medical Outcome Study SF-36 (MOS SF-36) and specialized Asthma Quality of Life Questionnaire (AQLQ).
Results. The increase in body mass index (BMI) in patients with asthma according to the questionnaires MOS SF-36 and AQLQ is associated with significant reductions in viability (r=–0.33, p<0.05), physical activity (r=–0.37, p<0.01), social activity (r=–0.36, p <0.01) and the degree of reduction of the patient's tolerance to adverse environmental factors (r=–0.29, p<0.05)
Conclusions. The presence of concomitant obesity in patients with asthma is associated with significant reductions in the parameters of physical and social activity, viability and with an increase in the subjective pain assessment (according to the questionnaire MOS SF-36) and characterized by significantly lower rates of activity, tolerance to adverse environmental factors and general life quality (according to the AQLQ questionnaire).
10
Korkmazov, M. Yu, M. A. Lengina, I. D. Dubinets, A. M. Korkmazov, and A. A. Smirnov. "Opportunities for correction of individual links of the pathogenesis of allergic rhinitis and bronchial asthma with assessment of the quality of life of patients." Meditsinskiy sovet = Medical Council, no. 4 (April 5, 2022): 24–34. http://dx.doi.org/10.21518/2079-701x-2022-16-4-24-34.
Full textAbstract:
Introduction. One of the antileukotriene drugs for the treatment of bronchial asthma and allergic rhinitis with and without polyposis is montelukast. The presented article presents the results of the analysis of the effectiveness, safety and impact on the quality of life of patients, the use of the singular, in various forms of allergic rhinitis and associated comorbid conditions.Aim of the study. To assess the impact on the quality of life of patients, the effectiveness and safety of the use of montelukast in the complex therapy of patients with allergic rhinitis and comorbid diseases.Materials and methods. A simple, blind, randomized, controlled clinical trial involved 97 patients divided into 4 groups: patients with moderate allergic rhinitis; allergic rhinitis of moderate severity and bronchial asthma; severe allergic rhinitis and bronchial asthma; severe allergic rhinitis, bronchial asthma and polypous rhinosinusitis. In parallel with the comparison of drug tolerability, safety and clinical symptoms (rhinorrhea, nasal congestion, itching, sneezing, bronchopulmonary manifestations), the quality of life was assessed using a special SNOT-22 questionnaire.Results. The use of the antileukotriene drug montelukast in the complex therapy of allergic rhinitis and related comorbid conditions significantly improved the clinical symptoms and quality of life of patients over the entire period of treatment in all groups. There was an increase in the suppression of leukotriene-mediated effects when using montelukast, more in the group of people with allergic rhinitis and bronchial asthma, such as symptoms of the allergic triad, mucus hypersecretion, bronchospasm, eosinophilia, increased vascular permeability, etc.Conclusion. In the treatment of patients with allergic rhinitis and morbid conditions, Singular has demonstrated an inhibitory effect on cysteinyl leukotrienes, high bioavailability, good tolerability and safety.
11
Barakat, Nermeen Mahmoud Abd Elaziz. "Effect of risk factors of bronchial asthma on elderly health related quality of life at assiut university hospital, Egypt." International Journal of Advanced Nursing Studies 6, no. 1 (December 29, 2016): 1. http://dx.doi.org/10.14419/ijans.v6i1.6910.
Full textAbstract:
The present study aimed to assess quality of life of elderly asthmatics and to determine risk factors that may influence it. The study was carried out in the chest out-patient clinics and chest departments at Assiut University Hospital. The sample type of this study total coverage during one year consists of one hundred and five elderly people aged 60 years and above suffering from bronchial asthma disease. Two tools were used for data collection, tool one divided into three parts, socio-demographic data risk factors assessment, and history of bronchial asthma. Tool two to assessment health related quality of life of asthmatic patients was using St. George's Respiratory Questionnaire (SGRQ). The main results yielded by the study proved that, there were highly significant differences between risk factors of bronchial asthma disease and health-related quality of life. The study recommended that further research be implemented to improve the effect of health related quality of life for asthmatic patients.
12
Velichko, Valentyna I., Yana I. Bazhora, Galyna O. Danilchuk, and Larysa I. Kolotvina. "PSYCHOEMOTIC FEATURES, STATUS OF COGNITIVE FUNCTIONS AND ASSESSMENT OF BRONCHIAL ASTHMA PATIENTS’ QUALITY OF LIFE." Wiadomości Lekarskie 72, no. 4 (2019): 657–63. http://dx.doi.org/10.36740/wlek201904130.
Full textAbstract:
Introduction: The worldwide pandemic of bronchial asthma (BA) is creating severe challenges for health care specialists. Asthma patients feature a number of psycho-emotional and cognitive impairments, mark the reduction of quality of life which limits response to therapy. The aim: to investigate psycho-emotional features, state of cognitive function and assess bronchial asthma patients quality of life. Materials and methods: 142 patients (61 men and 81 women) with bronchial asthma aged 19 - 57 y.o. were examined. The main group consisted of 78 patients with an uncontrolled course of asthma (UCBA). 64 patients with controlled asthma (CBA) were included in the comparison group. The subjective assessments of quality of life by questionnaire SF-36, assessment of asthma-dependent quality of life (AQLQ) was made. The patients’ emotional and psychological profile was assessed using the following tests and scales: MMSE, Montreal Scale for Assessing Cognitive Function, Hospital Alert and Depression (HADS) scale with a qualitative and quantitative assessment of the results. Results: According to the results obtained, the averaged profiles of the patients’ quality of life demonstrated the negative effects of asthma, especially its uncontrolled form. There were statistically significant differences in the quality of life in patients with UCBA according to the five criteria of the MOS SF-36 questionnaire as compared to the CBA group ( physical functioning, role-playing, caused by physical condition, general health, social functioning, viability). A comparison of the specific quality of life with the help of the AQLQ questionnaire revealed a significant negative effect of the uncontrolled course of the illness on the patients’ quality of life. The correlation analysis of the relationship between the course of asthma and the parameters of a specific life qality showed a close correlation between the level of asthma control and the overall evaluation of specific quality of life (r = 0 , 62; p < 0.001). The results of neuropsychological examinations in UCBA patients showed the presence of light predemention cognitive impairments. Manifestations of anxiety-depressive disorders were found in 44 (56.41%) patients in the main group, while in the comparison group, the symptoms of anxiety and depression were observed in 14 (21.88%) cases. Patients with UCBA noted a higher level of anxiety (11.5 ± 1.2 versus 6.9 ± 1.4, p <0.05), depression (8.3 ± 2.3 versus 5.6 ± 3.9) on the HADS scale compared with patients with CBA Conclusion: The psycho-emotional features revealed in UCBA patients can determine the prognosis of the disease and justify the expediency of additional diagnostic and therapeutic psychotherapeutic measures.
13
Sobko, E. A., I. V. Demko, A. Yu Kraposhina, N. V. Gordeeva, O. P. Ischenko, S. A. Egorov, D. N. Okulova, N. S. Smolnikov, and A. I. Avdeeva. "Assessment of life quality indicators and the role of commitment in achieving control in severe bronchial asthma." Meditsinskiy sovet = Medical Council, no. 16 (October 29, 2021): 45–51. http://dx.doi.org/10.21518/2079-701x-2021-16-45-51.
Full textAbstract:
Introduction. One of their main aspects in the treatment of patients with bronchial asthma is maintaining adequate control over the course of the disease.The aim: to assess the level of control, the causes of the uncontrolled course of the disease and the quality of life in patients with severe bronchial asthma.Materials and methods. The study involved 160 patients with severe bronchial asthma taking basic anti-inflammatory therapy. The assessment of adherence to baseline therapy was assessed by questionnaires of patients with a modified Morisky-Green questionnaire and a test to assess adherence to inhalers (TAI). A quality of life questionnaire for patients with bronchial asthma (AQLQ) was used to assess quality of life.Results. It was revealed that all patients had reported daily symptoms and a daily need for short acting beta-agonists; 96.6% of the patients enrolled in the study had night awakenings and physical activity restriction. The survey of patients with the help of the Morisky-Green questionnaire showed that deliberate low adherence to therapy was noted in 45.6% of cases, which was formed due to inattention to the hours of medication – 67.1% and missing the drug in good health in 47.9% of patients. Low motivation and low awareness of their disease is recorded in 24.4% of patients.Conclusions. All patients did not achieve control of the disease. In half of patients with severe asthma, there is low deliberate adherence to basic anti-inflammatory therapy, which is formed mainly by missing the drug in good health and inattention to the hours of medication. Asthma symptoms have the greatest impact on the patient’s emotional state, physical activity, and overall quality of life.
14
Cherniakova, A. E., T. S. Ospanova, and I. S. Karmazina. "Allergic Rhinitis and Quality of Life in Patients with Bronchial Asthma." Ukraïnsʹkij žurnal medicini, bìologìï ta sportu 2, no. 2 (May 24, 2017): 128–32. http://dx.doi.org/10.26693/jmbs02.02.128.
Full text
15
Shereen Ahmed Ahmed Qalawa. "Health locus of control related daily living activities during COVID 19 pandemic as an indicator of Bronchial Asthma." World Journal of Advanced Research and Reviews 13, no. 2 (February 28, 2022): 031–42. http://dx.doi.org/10.30574/wjarr.2022.13.2.0123.
Full textAbstract:
Background: Bronchial asthma is a widespread chronic airway inflammatory disease, and it is characterized by paroxysmal or continual respiratory manifestations and airway airflow limitations. Accordingly, coronavirus disease 2019 (COVID-19) impact on quality of life including daily living activities come into views to be highly misjudged, especially in patients who have not been admitted to the hospital. Aim: To find out relationship between health locus of control and daily living activities among adult patients with bronchial asthma during Covid 19 Pandemic at Port- said city in Egypt. Subject and methods: A descriptive cross-sectional study was carried out on a total of 230 adult patients from both sex with bronchial asthma attend medical chest clinics in Alsalam, Por – fouad, Algawhara governmental hospital at Port-said city, Egypt responded to the self-administered survey and excluded patients with co- morbid diseases and were refused to participate in the study using self-administered survey divided into three main parts. First part consist of 8 items related to demographic data, second part: Patient's knowledge regarding bronchial Asthma adapted from Williams., 2005, third part: it adapted from Putman., 2004 to assess the effect of covid 19 on bronchial asthma patient's daily living activities and locus of control. Results: there are a statistically significant relation between total scores of locus of asthma control and smoking pattern ps= (o, oo3) with total Mean scores and SD 28.52 ± 4.43. Also, there are a positive correlation between total daily living activities scores and total locus of control among patients with Bronchial Asthma. Finally, there are a statistically significant relation between total daily living activities scores and Bronchial Asthma patients and their socio-demographic characteristics only in the items related to patient's residence Ps=( 0.082) . Conclusion: Patient with Bronchial Asthma need for receive regular; periodic in-service coping program contains methods of adherence with their daily living activities, knowledge of their disease which indirectly added stressor on patient's life and indirectly affect their disease management and coping especially in the period of Corona virus Pandemic which added stressors of those patients. Further studies are needed to study the coping strategies that influence bronchial Asthma patient's locus of control, management and coping with their disease with a large geographical areas and sampling.
16
Vázquez, Maria Isabel. "Relationships between Psychological Variables Relevant to Asthma and Patients' Quality of Life." Psychological Reports 86, no. 1 (February 2000): 31–33. http://dx.doi.org/10.2466/pr0.2000.86.1.31.
Full textAbstract:
The relationships between health-related quality of life and various psychological variables relevant to the clinical evolution of bronchial asthma were evaluated for 101 asthma patients ages 14 to 72 years. Scores on quality of life exhibited a significant negative correlation with perceived vulnerability, panic-fear personality, and irritability, fatigue, airway obstruction, hyperventilation, and panic-fear during attacks but was not significantly correlated with preventive behaviour, attack-related behaviour, recognition, and control of respiratory function, or quality of care. These results imply that the effects of the former group of variables should be taken into account when assessing asthmatic patients' quality of life.
17
Li, Zhilu, Bingxi Xu, Yingjing Du, Xiaomin Zhuang, Yuxuan Wang, Saijia Li, Honghai Li, and Pingping Yan. "Research Progress of Vitamin D and Pathogenesis of Bronchial Asthma." Journal of Advances in Medicine Science 3, no. 3 (October 29, 2020): 31. http://dx.doi.org/10.30564/jams.v3i3.2439.
Full textAbstract:
At present the incidence of bronchial asthma on the rise, its pathogenesis and the genetic immune and the relationship between social environment and other aspects are inseparable the activity of vitamin D (Vit D) in the body in the form of 1, 25 - (OH) 2 d3, mainly involved in bone metabolism and calcium absorption in addition to this, a growing number of studies show that in Vit D plays an important role in the pathogenesis of bronchial asthma, play a role in the immune function of bronchial asthma growth hormone sensitivity adjustment and airway remodeling in this paper, the development of a variety of mechanisms, such as Vit D. Review the possible mechanisms affecting bronchial asthma, hoping to provide adjuvant treatment for patients with bronchial asthma, discover new treatment approaches, and improve the quality of life for patients.
18
Gniadek, Agnieszka, Iwona Malinowska-Lipień, Paulina Solarz, and Elżbieta Marcisz. "Quality of life in patients with bronchial asthma treated with specific immunotherapy." Pielęgniarstwo XXI Wieku, no. 51 (October 28, 2015): 5–10. http://dx.doi.org/10.12923/p21w-2015-2/11.
Full text
19
Nenasheva, N. M. "New opportunities for treatment of severe bronchial asthma: from clinical studies to portraits of patients." Russian Journal of Allergy 12, no. 3 (December 15, 2015): 51–61. http://dx.doi.org/10.36691/rja456.
Full textAbstract:
The proportion of patients with controlled asthma has increased over the last 15 years, however, still there is a significant proportion of patients who do not achieve control of the disease, and therefore have a high risk of exacerbations, hospitalizations, and poor quality of life. Patients with severe asthma, for which there were limited additional pharmacotherapy are the major problem. For the first time in recent years in the treatment of asthma a new class of drugs appeared: longacting anticholinergics - tiotropium which had been entered in stepwise therapy of asthma by GINA 2015. The definition of severe asthma, the role of the cholinergic nervous system in bronchial asthma, mechanism of action and clinical efficacy of tiotropium in severe bronchial asthma adults are described in the article.
20
Jarosz, Marcin, Sadia Syed, Michał Błachut, and Karina Badura Brzoza. "Emotional distress and quality of life in allergic diseases." Wiadomości Lekarskie 73, no. 2 (2020): 370–73. http://dx.doi.org/10.36740/wlek202002131.
Full textAbstract:
Emotional disorders accompany many somatic diseases, especially ones with severe or chronic course, and such are allergic diseases. Long-term course of the disease, the need for chronic treatment and repeated exacerbations as well as symptoms of depression or anxiety have a significant impact on the quality of life of patients, constituting a serious burden both from the point of view of the individual and the society. The data evaluating emotional disturbances and their impact on the quality of life in three atopic diseases: bronchial asthma, atopic dermatitis and seasonal rhinitis were analysed. Mood disorders as well as mental and behavioral disorders due to alcohol abuse are the most common psychiatric disorders observed in patients with bronchial asthma. There are data indicating a relationship between the occurrence of allergic rhinitis and mood disorders, anxiety disorders and suicidal tendencies. Atopic dermatitis is associated with an increased risk of depressive and anxiety disorders and sleep disorders, and in children with more prevalence of behavioral disorders. Most studies highlighted the relationship between emotional disorders and quality of life in the above-mentioned patient groups. In addition to physical ailments, patients suffering from allergic diseases also report emotional problems that can adversely affect the course of the disease, the treatment process, and reduce quality of life. Therefore, these patients require a holistic approach with a more accurate assessment of emotional disorders.
21
Rakita, D. R., and D. S. Kuspanaliyeva. "THE INFLUENCE OF HYPERVENTILATION ON LIFE QUALITY OF PATIENTS WITH BRONCHIAL ASTHMA." I.P.Pavlov Russian Medical Biological Herald 20, no. 1 (December 15, 2012): 87. http://dx.doi.org/10.17816/pavlovj2012187-91.
Full text
22
Jankowska-Polanska, Beata, Izabella Uchmanowicz, Katarzyna Lomper, Bernard Panaszek, and Andrzej Fal. "552 Predictors Affecting the Quality of Life of Patients with Bronchial Asthma." World Allergy Organization Journal 5 (February 2012): S175. http://dx.doi.org/10.1097/01.wox.0000411667.00011.c5.
Full text
23
SKOROKHODKINA, O. V., R. A. SHAGVALIEVA, E. V. DEMYANOVA, A. V. BAGAUTDINOV, A. V. LUNTSOV, and E. V. DYAKOVA. "Biological therapy of severe bronchial asthma: organizational and clinical aspects, experience of organizing a specialized center." Practical medicine 19, no. 4 (2021): 14–19. http://dx.doi.org/10.32000/2072-1757-2021-4-14-19.
Full textAbstract:
Severe bronchial asthma is a serious medical and social problem of modern healthcare. It is characterized by a significant decrease in the quality of life of patients, high disability rate, potential mortality, and existing difficulties in organizing medical care. In turn, biological therapy of severe bronchial asthma is a highly effective method of treatment that can qualitatively change the disease prognosis. Currently, the Republic of Tatarstan is implementing a model of providing specialized medical care for severe bronchial asthma by organizing a regional Center for biological therapy of severe bronchial asthma at the multidisciplinary medical institution «Republic Clinical Hospital of the Ministry of Health of the Republic of Tatarstan». The article provides data on the principles of the Center functioning and presents the results of the authors’ clinical experience in biological therapy of severe bronchial asthma.
24
Ai, Jingang, Zuozhong Xie, Xiang Qing, Wei Li, Honghui Liu, Tiansheng Wang, and Guolin Tan. "Clinical Effect of Endoscopic Vidian Neurectomy on Bronchial Asthma Outcomes in Patients with Coexisting Refractory Allergic Rhinitis and Asthma." American Journal of Rhinology & Allergy 32, no. 3 (April 12, 2018): 139–46. http://dx.doi.org/10.1177/1945892418764964.
Full textAbstract:
Background The prevalence of both allergic rhinitis and bronchial asthma is high throughout the world; their mutual influence on each other has been documented in many studies. However, studies regarding surgical intervention are limited. Objective To evaluate the clinical significance of endoscopic vidian neurectomy on bronchial asthma outcomes in patients with coexisting refractory allergic rhinitis and asthma. Methods A total of 109 patients with moderate to severe persistent intractable allergic rhinitis and mild/moderate asthma were allocated to the bilateral endoscopic vidian neurectomy group (group 1) or conservative medication group (group 2) according to the patients’ self-selection. The Rhinoconjunctivitis Quality of Life Questionnaire, Visual Analog Scale, Asthma Quality of Life Questionnaire, Total Asthma Symptom Score, and medication scores were evaluated at six months, one year, and three years after undergoing the initial treatments. Multivariate analysis was performed to determine which triggers of asthma attacks were associated with improved asthma outcomes in patients. Results Ninety-five patients were followed up for at least three years. Postoperative scores of Rhinoconjunctivitis Quality of Life Questionnaire and Visual Analog Scale were significantly lower than preoperative scores during follow-up in group 1 and were significantly lower than those of group 2. Postoperative scores of Asthma Quality of Life Questionnaire at the three follow-up time points were higher than the preoperative scores in group 1. The Total Asthma Symptom Score was not significantly decreased in group 1. The medication scores for allergic rhinitis and asthma were gradually reduced after surgery. At the end of the follow-up, the improvement rates for allergic rhinitis and asthma were 90.6% and 45.3%, respectively. Asthma outcomes were significantly improved by controlling rhinitis symptoms in patients whose asthma attacks were induced by “rhinitis onset” or “weather change.” Conclusion Controlling allergic rhinitis symptoms by bilateral endoscopic vidian neurectomy can significantly improve asthma outcomes in patients whose asthma attacks are induced by rhinitis onset and/or cold air.
25
Ivanchuk, Yuliya, Ludmila Tribuntceva, Andrey Budnevsky, Yanina Shkatova, Evgeniy Ovsyannikov, and Roman Tokmachev. "Life Quality and Cytokines Profile in Patients with Asthma and Osteoarthritis." International Journal of Biomedicine 11, no. 2 (June 5, 2021): 137–40. http://dx.doi.org/10.21103/article11(2)_oa2.
Full textAbstract:
The objective of this study was to evaluate levels of leptin, adiponectin, IL-4, IL-6, TNF-α, oxidative damage, and antioxidant status in patients with bronchial asthma (BA), compared to patients who suffer from both BA and osteoarthritis (OA), and analyze the quality of life in such patients. Methods and Results: The study included 103 patients (34 men and 69 women) diagnosed with moderate asthma aged from 30 to 70 years (mean age of 58.52±7.14 years). The levels of IL-4, IL-6, TNF-α, adiponectin, leptin, total antioxidant status (TAS), and total oxidative damage (TOD) were measured. Two questionnaires were used in this study: Asthma Quality of Life Questionnaire (AQLQ) and Asthma Control Test (АСТ). The levels of leptin, TNF-α, and Il-6 were significantly higher in Group 2 than in Group 1. On the contrary, the IL-4 level was higher in Group 1 than in Group 2. The TAS value was significantly higher in Group 1 than in Group 2 (P=0.0001). The TOD value was significantly higher in Group 2 than in Group 1 (P=0.0000). The domains of AQLQ(S) activity, symptoms, and emotions were decreased in patients of Group 2. The values of the ACT test were 18.0±2.61 points and 16.78±1.92 points in Group 1 and Group 2, respectively (P=0.0077). Conclusion: In patients with both asthma and osteoarthritis, levels of inflammatory cytokines, such as leptin, IL-6, and TNF-α, are significantly elevated as well as values of total oxidative status, which correlate with poorer asthma control and quality of life.
26
K., Noushadali A., Uma Mohandas, and Thaha Hussain. "Assessment of health-related quality of life in paediatric asthma patients." International Journal of Contemporary Pediatrics 5, no. 4 (June 22, 2018): 1255. http://dx.doi.org/10.18203/2349-3291.ijcp20182078.
Full textAbstract:
Background: Bronchial Asthma is one of the important chronic disease in children. This disease can affect the children mentally and physically in various aspects. Health related quality of life (HRQoL) has become an increasing important issue in the management of Asthma and it is how often used to evaluate the effectiveness of antiasthma drugs. The objectives of the study are to assess the health-related quality of life in Pediatric patients by using Pediatric Asthma quality of life questionnaire and also to assess the impact of parent education in health-related quality life of Asthma patient. The other intention of the study is to determine the anti-asthma drugs utilisation pattern in Pediatric patients.Methods: This study was conducted in in-patient and out-patient department of tertiary care Hospital for a period of 1 year. 145 pediatric patients were participated in this study. A comparative study was conducted to describe the HRQoL in asthma and the pediatric asthma quality of life questionnaire is used to determine the HRQoL of the subjects. Statistical analysis was performed using the instant prism ANOVA test and the Bartlett’s test. P <0.05 was considered statistically significant.Results: This study shows that asthma is more common in male compared to female and most common type was Mild Persistent (47.85). Most of the patient are treated with bronchodilator (71%) followed by steroid (49%) and Leukotrien Antagonist (30.43%). Also revealed that most of the patients are taking multiple drug therapy compared to mono therapy. Quality of life having significant difference in all domains by comparing first visits score. Those suffering from the intermittent type of asthma showed higher mean quality of life score in all domains by comparing first visit score vs second visit score vs third visit score.Conclusions: The health-related quality of life having improvement in all domain and overall quality of life by comparing the initial visit to the follow up visits. The patient education plays major role in improving the quality of life of pediatric population and the quality of life score having relationship with gender, age educational status, severity of asthma and the drug utilization improving health related quality of life.
27
Tymchenko, Hanna. "PREDICTION OF TREATMENT EFFECTIVENESS IN PATIENTS WITH ASTHMA-COPD OVERLAP COMBINED WITH HYPERTENSION." Eastern Ukrainian Medical Journal 8, no. 2 (June 29, 2020): 115–22. http://dx.doi.org/10.21272/eumj.2020;8(2):115-122.
Full textAbstract:
Introduction. Recently, there has been an increase in the prevalence of comorbid conditions, including a combination of bronchial asthma and chronic obstructive pulmonary disease, called asthma-chronic obstructive pulmonary disease overlap, and their combination with hypertension. The presence of combined pathology causes an increase in the severity of symptoms and functional disorders, in numbers of exacerbations, deterioration of quality of life and tolerance to exercise, and also causes difficulties in selecting a comprehensive treatment for this group of patients. That is why the aim of our study was to optimize and predict the effectiveness of treatment of patients with bronchial asthma in combination with the chronic obstructive pulmonary disease on the background of hypertension based on assessing the dynamics of clinical and laboratory and functional status in different treatment regimens. Materials and methods. 100 patients with bronchial asthma in combination with the chronic obstructive pulmonary disease on the background of hypertension were selected. Patients underwent: general clinical examination, determination of respiratory function, clinical blood tests and enzyme-linked immunosorbent assays, questionnaires to determine symptoms and quality of life, as well as a functional study with a six-minute walk test in the dynamics of complex basic treatment with the physical rehabilitation program. Research results. Adding an active rehabilitation program to standard medical treatment significantly improves the bronchial response to the action of bronchodilators according to the spirometry, reduces clinical manifestations, shortness of breath, and improves the quality of life and exercise tolerance. The presence of such criteria as the forced expiratory volume in 1 second < 69%, the forced expiratory flow 50% < 21.6% and the forced expiratory flow 75% < 31.65%, C-reactive protein > 7.6 g / l, interleukin 8 > 18.13 pg/ml may provide tolerance to the program of physical rehabilitation and the inexpediency of its use. Conclusions. Under the influence of rehabilitation measures applied by us, patients experienced some positive changes in cardiovascular and respiratory function, exercise tolerance, and quality of life, although some patients do not respond to the addition of a comprehensive rehabilitation program associated with such baseline parameters as forced expiratory volume in 1 second, forced expiratory flow 50% and the forced expiratory flow 75%, C-reactive protein, interleukin 8
28
Shogenova, Madina S., Svetlana H. Hutueva, and Laura S. Shogenova. "Principles of modern diagnosis and treatment of atopic dermatitis and bronchial asthma: Clinical case." Terapevticheskii arkhiv 94, no. 3 (March 15, 2022): 427–33. http://dx.doi.org/10.26442/00403660.2022.03.201430.
Full textAbstract:
This article presents the experience of successful use of the drug dupilumab in a patient with severe atopic dermatitis and bronchial asthma. The effectiveness of biological therapy with dupilumab 300 mg subcutaneously for 52 weeks of T-2 associated diseases, including a combination of severe atopic dermatitis and bronchial asthma, uncontrolled course based on the case history of patient Ts., born in 2006 with the diagnosis "Main: atopic dermatitis, common form, severe course. Concomitant diagnosis: bronchial asthma, persistent course, uncontrolled, moderate severity". Dynamic monitoring of the total blood count with the calculation of the absolute number of eosinophils in peripheral blood was performed. The study showed high efficacy and safety of biological therapy with dupilumab 300 mg subcutaneously every 2 weeks for 52 weeks with a combination of severe atopic dermatitis and bronchial asthma, uncontrolled course in patient Ts (Born in 2006). The examination of the ALEX2 allergochip made it possible to establish the molecular components of the primary causal allergens, predict the course of an allergic disease, and carry out successful elimination measures against food allergens, preserving the maximum set of nutrients in the patient's diet. Dupilumab therapy in severe atopic dermatitis and uncontrolled bronchial asthma leads to clinically significant improvement in the course of diseases, control of disease symptoms. Atopic dermatitis shows a decrease in itching of the skin, normalization of sleep, improvement of quality of life. With bronchial asthma, a reduction in exacerbations, normalization of respiratory function indicators, complete control of the disease has been achieved. The targeted biological drug dupilumab has a targeted effect on the key links in the pathogenesis of atopic dermatitis and bronchial asthma and reduces the burden of severe diseases. Therefore, the use of dupilumab in atopic dermatitis and bronchial asthma contributes to achieving disease control and improving the patient's quality of life.
29
Gangadharan, Aswathi, Diya Sheela Thomas, ,. Harshida, Cyril Tom, and Prabhakar Adake. "The Role of Clinical Pharmacist in Enhancement of Medication Adherence and Quality of Life in Bronchial Asthma and Chronic Obstructive Pulmonary Disease." Journal of Drug Delivery and Therapeutics 11, no. 4-S (August 15, 2021): 48–53. http://dx.doi.org/10.22270/jddt.v11i4-s.4952.
Full textAbstract:
Asthma and Chronic Obstructive Pulmonary Disease (COPD) are two of the leading causes of morbidity, mortality and economic burden worldwide. The burden of chronic respiratory disease has major adverse effects on the quality of life and ability of affected individuals. A variety of effective treatment options exist for patients with Asthma and COPD but long-term adherence to medications is required for treatment success. Aim of the study was to assess the adherence to medication and quality of life in Asthma and COPD patients using questionnaires, and to enhance adherence and quality of life using the strategies of counselling and education. The observational study was conducted for a period of 6 months, assessed medication adherence by Morisky self-reported questionnaires and quality of life by St. George’s Respiratory questionnaire (SGRQ) and 36 item short form health survey (SF-36). The study shows there was statistically significant improvement in medication adherence score (p<0.05) and quality of life (p<0.05) after pharmacist’s counselling regarding disease, medication and lifestyle. Comparison between various demographic factors like age, gender, co-morbidities, smoking index showed equal impact of pharmacist’s counselling on improvement of overall medication adherence and quality of life in Asthma and COPD patients. Overall medication adherence and quality of life improvement was found to be statistically significant in Asthma and COPD patients after counselling by clinical pharmacists. Clinical pharmacists must be considered as an integral element of healthcare system. Patient counselling is effective to resolve the problems associated with medication non-adherence and quality of life.
Keywords: Asthma, COPD, Medication adherence, Quality of life
30
Scichilone, Nicola, Fulvio Braido, Salvatore Taormina, Elena Pozzecco, Alessandra Paternò, Ilaria Baiardini, Vincenzo Casolaro, Giorgio Walter Canonica, and Vincenzo Bellia. "Is Health-Related Quality of Life Associated with Upper and Lower Airway Inflammation in Asthmatics?" BioMed Research International 2013 (2013): 1–7. http://dx.doi.org/10.1155/2013/539290.
Full textAbstract:
Background.Allergic diseases impair health-related quality of life (HR-QoL). However, the relationship between airway inflammation and HR-QoL in patients with asthma and rhinitis has not been fully investigated. We explored whether the inflammation of upper and lower airways is associated with HR-QoL.Methods.Twenty-two mild allergic asthmatics with concomitant rhinitis (10 males, 38 ± 17 years) were recruited. The Rhinasthma was used to identify HR-QoL, and the Asthma Control Test (ACT) was used to assess asthma control. Subjects underwent lung function and exhaled nitric oxide (eNO) test, collection of exhaled breath condensate (EBC), and nasal wash.Results.The Rhinasthma Global Summary score (GS) was 25 ± 11. No relationships were found between GS and markers of nasal allergic inflammation (% eosinophils: , ; ECP: , ) or bronchial inflammation (pH of the EBC: , ; bronchial NO: , ; alveolar NO: , ). The mean ACT score was 18. When subjects were divided into controlled (ACT ≥ 20) and uncontrolled (ACT < 20), the alveolar NO significantly correlated with GS in uncontrolled asthmatics (, ).Conclusions.Upper and lower airways inflammation appears unrelated to HR-QoL associated with respiratory symptoms. These preliminary findings suggest that, in uncontrolled asthma, peripheral airway inflammation could be responsible for impaired HR-QoL.
31
Shartanova, N. V. "INFLUENCE OF DELIVERY ON PATIENTS’ ADHERENCE TO THERAPY OF BRONCHOOBSTRACTIVE DISEASES." Russian Journal of Allergy 11, no. 5 (December 15, 2014): 40–45. http://dx.doi.org/10.36691/rja515.
Full textAbstract:
Bronchial asthma (BA) - a global public health problem worldwide. All treatments aimed at improving the control of symptoms of the disease, prevention of exacerbations and improving the quality of life for patients. The use of inhalation therapy is the basis for the treatment of all bronchoobstructive diseases. The effectiveness of treatment depends not only on the quality of the inhaled drug, but also by means of delivery of the drug into the bronchi. Easyhaler - a new dry powder inhaler, inhalation activated enables precise dosing of the drug. According to various studies, the method of delivery of drugs has proven high efficiency, ease to use and adherence of patients to the unit.
32
Elkholy, Maha M., Mahmoud Hassan Khedr, and Ashraf Halawa. "Impact of Allergic Rhinitis on Quality of Life in Patients with Bronchial Asthma." International Journal of Health Sciences 6, no. 2 (June 2012): 186–94. http://dx.doi.org/10.12816/0005996.
Full text
33
Verma, Shalini, Shally Awasthi, and Sarika Gupta. "Association of Self-Reported Quality of Life in Children with Level of Bronchial Asthma Control." Asian Journal of Clinical Pediatrics and Neonatology 8, no. 2 (July 9, 2020): 16–22. http://dx.doi.org/10.47009/ajcpn.2020.8.2.4.
Full textAbstract:
Background: To assess the association of self-reported quality of life (QOL) by using mini- pediatric asthma quality of life questionnaire (mini-PAQLQ) in children aged between 7-15 years with a level of asthma control. Subjects and Methods: Prospective observational study conducted in the asthma clinic in the outpatient department from September 2016 to August 2017. All the cases of asthma, as defined by GINA guidelines, aged between 7-15 years with parental consent were recruited. The level of control was also assessed according to GINA guidelines. Excluded were clinically suspected cases of chronic lung diseases except for bronchial asthma and any other chronic medical condition. QOL was assessed by using mini-PAQLQ which had three domains i.e. Symptoms, emotions and limitation of activity. Each domain had questions and their responses coded on a visual scale with 7 options. Results: From September 2016 to August 2017, total enrolled were 85 of which 51 (60%) were partly controlled and 34(40%) were well controlled. Mean mini-PAQOL score in patients with partly control was low (3.59 0.93) as compared to those with well-controlled asthma (5.83 1.21) (p=0.0001). Conclusion: Self-reported QOL of children with partly controlled asthma was found to be impaired in all the domains as compared to those with well-controlled asthma.
34
Perel’man, N. L., and V. P. Kolosov. "Long-term change in health-related quality of life in patients with asthma." Russian Pulmonology 28, no. 6 (February 16, 2019): 708–14. http://dx.doi.org/10.18093/0869-0189-2018-28-6-708-714.
Full textAbstract:
The aim of this study was to investigate long-term change in health-related quality of life (HRQL) in patients with asthma in real clinical practice and in relation to emotional disorders, cooperativeness (cooperation between the patient and the physician, and adherence to treatment), and cold air-provoked bronchial hyperresponsiveness (BHR).Methods. This observational study involved 32 patients with mild to moderate asthma. The study duration was 7.5 to 10 years. HRQL was assessed using SF-36 questionnaire and Asthma Quality of Life Questionnaire (AQLQ); emotional disorders were diagnosed using Hospital Anxiety and Depression Scale (HADS). Patients’ cooperativeness assessment was based on number of a patient’s scheduled visits to a physician during the study. The asthma control level was evaluated using the Asthma Control Test (ACT).Results. A significant worsening was found in the social activity domain of HRQL in the total group of the patients. According to AQLQ, a significant improvement was seen in the activity and symptoms domains and in the total score of quality of life (QoL). Long-term pharmacological treatment of asthma decreased anxiety and depression levels. The asthma control (ACT score) increased from 13.2 ± 1.0 to 19.7 ± 1.1 (р = 0.00003). Anxiety and depression decreased in patients with high cooperativeness during the long-term follow-up, while the total QoL and the specific QoL were unchanged excluding the social activity domain. A significant worsening in the activity scale and in the emotional scale of specific QoL together with growing depression and decreasing control of asthma were found in patients with lower cooperativeness. The cold air-provoked BNR slowed down the long-term improvement in the social activity domain. The cold air-provoked BNR also decreased patient-reported evaluation of daily activity.Conclusion. The long-term basic therapy of asthma provides a positive trend in HRQL in the real clinical practice independently on worsening of the disease. Lower cooperativeness of a patient could decrease specific QoL, which, in turn, worsens the control of asthma and contributes to negative emotional background and destructive behavior.
35
Ignatova, G. L., E. V. Blinova, and O. L. Minakina. "Clinical efficacy of anti-ige-therapy in adult patients with severe uncontrolled bronchial asthma in real clinical practice." Medical Council, no. 15 (October 12, 2018): 54–58. http://dx.doi.org/10.21518/2079-701x-2018-15-54-58.
Full textAbstract:
The article presents the results of comprehensive assessment of the efficacy of anti-IgE therapy in adult patients with severe IgE-mediated uncontrolled bronchial asthma in real clinical practice. Omalizumab added to the background anti-inflammatory therapy allowed to reduce the incidence of asthma exacerbations, achieve stable positive dynamics during severe asthma and associated allergic diseases, increase control of the disease, and improve the patients’ quality of life. The drug has a wellcharacterized long-term use safety profile.
36
Fassakhov, R. S. "Severe eosinophilic asthma: therapeutic potential of Reslizumab." Medical Council, no. 15 (October 12, 2018): 70–75. http://dx.doi.org/10.21518/2079-701x-2018-15-70-75.
Full textAbstract:
The review discusses the problems associated with the treatment of patients with severe resistant to therapy asthma: prevalence, socio-economic burden, impact on quality of life. The phenotype of bronchial asthma with eosinophilic inflammation, frequency of occurrence, clinical features, and modern approaches to therapy are discussed in detail, including the use of a drug of monoclonal antibodies against interleukin 5-reslizumab.
37
Zaytseva, Svetlana V., Anna U. Tomilova, Olga V. Zaytseva, Olga B. Voronina, Olga A. Murtazaeva, Valeriy A. Mukhortykh, and Irina N. Tsymbal. "Genetically Engineered Biologic Drugs in Management of Children with Bronchial Asthma." Pediatric pharmacology 18, no. 6 (November 16, 2021): 460–68. http://dx.doi.org/10.15690/pf.v18i6.2325.
Full textAbstract:
Current article represents the modern clinical guidelines on management of severe bronchial asthma (BA) in children and practical use of genetically engineered biologic drugs. Clinical efficacy and safety of omalizumab has its special role. Efficacy analysis was carried out in real-life' clinical setting (considering high economical expenses of biological treatment) to estimate effective response predictors and principles of patients selection for such therapy. Two years of anti-IgE treatment experience in inpatient pediatric department settings demonstrates that omalizumab inclusion to treatment of children with severe asthma resistant to standard therapy allows to solve asthma symptoms, to forgo high doses inhaled glucocorticosteroids, to improve lung function parameters, and to increase significantly quality of life in 95% of our patients.
38
Khamitov, R. F., L. Yu Palmova, and V. G. Novozhenov. "Antibacterial therapy in patients with bronchial asthma and latent Mycoplasma pneumoniae infection." PULMONOLOGIYA, no. 1 (February 28, 2007): 64–68. http://dx.doi.org/10.18093/0869-0189-2007-0-1-64-68.
Full textAbstract:
Influence of Mycoplasma pneumoniae (Мр) infection on asthma course and quality of life (QoL) of asthmatic patients was studied. Mp infection was diagnosed using specific immunoglobulins and PCR. The 6-week course of antibacterial therapy with azithromycin (Zitrolidum) was administered followed by analysis of clinical features and QoL. The latter was done using the AQLQ questionnaire with consideration of gender, asthma severity, contamination with and Мp eradication. Negative influence of Мp on clinical course of asthma and QoL was found. Therapy with Zitrolidum led to Мp eradication in 43 % of the cases, clinical improvement and increasing QoL in successfully treated patients. The results allow recommendation of azithromycin as a possible addition to the basic therapy of patients with severe asthma and laboratory signs of Mp infection.
39
Zhang, Juan, Junmin Zhang, Fengxia Shi, Wei Tian, and Xiuzhen Liu. "Therapeutic effect of a combination of montelukast and vitamins A and D drops in children with bronchial asthma, and its influence on quality of life." Tropical Journal of Pharmaceutical Research 20, no. 9 (November 14, 2021): 2005–11. http://dx.doi.org/10.4314/tjpr.v20i9.30.
Full textAbstract:
Purpose: To investigate the efficacy of a combination of montelukast and vitamins A and D drops in bronchial asthma children, and its effect on quality of life.Methods: Sixty bronchial asthma children from June 2018 to June 2020 were collected and randomized into study group and control group (30 cases in each group). Control group received montelukast sodium (chewable tablets), while the study group received vitamins A and D drops (capsules) plus. Clinical efficacy, lung function, serum inflammatory factors, and quality of life were evaluated and compared.Results: Compared with control group, total treatment effectiveness was higher and the symptom remission period was shorter in the study group (p < 0.05). Post-treatment, the parameters of FEV1 and FVC increased in both groups, but higher in the study group (p < 0.05). Serum levels of CRP and IL-4 in both groups decreased after treatment, while serum IL-10 levels were significantly up-regulated. Compared with control group, the levels of these indicators were improved in the study group (p < 0.05). Post-treatment Chinese Version of Pediatric Quality of Life Asthma Specific Scale (PedSQL) score was higher than before treatment, with higher values (for all indicators) in the study group (p < 0.05).Conclusion: The combination therapy of montelukast and vitamins A and D drops produces good clinical efficacy in children with bronchial asthma. It significantly shortens the time taken for relief of clinical symptoms, improves lung function, reduces inflammatory response, controls asthma, and improves the quality of life of the patients.
40
Feshchenko, Yu I., L. A. Iashyna, G. L. Gumeniuk, V. I. Ignatieva, M. A. Polianska, S. G. Opimakh, I. V. Zvol, S. M. Moskalenko, N. A. Vlasova, and L. A. Halai. "THE EFFICACY OF COMBINED THERAPY IN PATIENTS WITH NEUTROPHILIC BRONCHIAL ASTHMA." Asthma and allergy 2021, no. 4 (2021): 14–20. http://dx.doi.org/10.31655/2307-3373-2021-4-14-20.
Full textAbstract:
THE EFFICACY OF COMBINED THERAPY IN PATIENTS WITH NEUTROPHILIC BRONCHIAL ASTHMA Yu. I. Feshchenko, L. A. Iashyna, G. L. Gumeniuk, V. I. Ignatieva, M. A. Polianska, S. G. Opimakh, I. V. Zvol, S. M. Moskalenko, N. A. Vlasova, L. A. Halai State organization «F. G. Yanovsky National institute of phthisiology and pulmonology National Academy of medical sciences of Ukraine» , Kyiv, Ukraine Abstract. Background: Issues of neutrophilic bronchial asthma remain unresolved and the investigations of the pathogenesis and treatment of this disease endotype are currently continuing. The aim of the study: This study aimed to develop the technology of the treatment of the neutrophilic asthma with the use of available drugs in Ukraine. Methods. The study involved 30 patients with neutrophilic asthma. The first (control) group consisted of 15 patients who received standard therapy with a combination of budesonide and formoterol. The second (main) group consisted of 15 patients who received the treatment according the technology (ultrafine beclomethasone dipropionate, formoterol, tiotropium bromide and additionally for the first 10 days — inhalation of 10.0 % acetylcysteine solution through a nebulizer). All patients were surveyed with the Asthma Control Test (ACT), the Asthma Control Questionnaire (ACQ). The quality of life of patients was assessed by a St. George’s Respiratory Questionnaire. All patients underwent spirometry and a 6-minute walking test (6MWT). Results: In the prescription of complex therapy to patients with neutrophilic asthma clinical and functional efficacy was achieved in 93.3 % of patients. There were observed statistically significant increase in the ACT from (14.3 ± 1.3) to (20.3 ± 0.8) points (p < 0.05), a decrease in the ACQ from (2.3 ± 0.2) ) to (1.1 ± 0.1) points (p < 0.05), clinically significant reduction in the number of symptoms from (71.4 ± 5.6) points to (51.3 5.0) points, p < 0.05 according to the results of the St. George’s Respiratory Questionnaire, and a statistically significant increase in MEF50 from (28.9 ± 4.5) % to (41.6 ± 4.2) %, p < 0.05, MEF25 — from (19.1 ± 2.9) % to (27.6 ± 2.6) %, p < 0.05 and FEV1 /FVC from (67.2 ± 3.5) % to (76.1 ± 2.3) %, p < 0.05 after 3 months of complex treatment, as well as a statistically significant increase in the number of meters passed in the 6MWT from (266.3 ± 16.2) m to (312.0 ± 14.4) m, p < 0.05, reduction of shortness of breath on the Borg scale before test from (2.5 0.3) points to (1.5 ± 0.1) points, p < 0.05 and after the test — from (4.1 ± 0.3) points to (3.1 ± 0.3) points, p < 0.05. Conclusions: The technology of treatment of patients with neutrophilic asthma allows to improve the control of the asthma symptoms and quality of life of the patients, bronchial patency at the small airways and reduce fixed bronchial obstruction, as well as increase exercise tolerance. Key words: bronchial asthma, neutrophilic inflammation, combined therapy.
41
SHAMSUTDINOVA, N. G., E. R. KIRILLOVA, D. M. GAYSINA, A. M. FATYKHOVA, E. V. DYAKOVA, N. S. SPIRIDONOVA, and L. I. MINGAZOVA. "Cognitive disorders in patients with bronchial obstructive syndrome." Practical medicine 19, no. 4 (2021): 69–74. http://dx.doi.org/10.32000/2072-1757-2021-4-69-74.
Full textAbstract:
Bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) lead to chronic hypoxia associated with cognitive impair-ment drastically worsening the quality of life of patients. The purpose — to study the degree of cognitive impairment in patients with bronchial asthma and COPD hospitalized in the Pulm-onology Unit of Republic Clinical Hospital. Material and Methods. The study included 27 patients divided into two groups: 20 patients with bronchial asthma and 7 patients with COPD. All the participants were subjected to spirometry, pulse oximetry, and 6-minute walking test. Assessment of cognitive func¬tions was carried out with MoCA test, MMSE questionnaire, and Mini-Cog test. Results. No connection between gender and cognitive functions tests and between the diseases and cognitive functions tests were found with Mann — Whitney test. However, after the correlation analysis was performed, it revealed an association of Mini-Cog test results and pulmonary failure degree (p = 0,091083). Analysis of the correlation between cognitive disorders and pulmonary failure showed that the degree of pulmonary failure correlates with the Mini-Cog test results (p < 0,01). It proves the interconnection between cognitive deficit and pulmonary failure. Patients with bronchial obstructive syndrome showed a reliable correlation of cognitive disorders with age (p < 0,008) and pulmonary failure (р < 0,04). The research proved that patients with pulmonary failure degree 2 have more expressed cognitive disorders than patients with pulmonary failure degree 1. Conclusion. In patients with asthma and COPD the cognitive impairment was diagnosed, its severity correlating with the de¬gree of pulmonary failure.
42
Tribuntseva, L. V., A. V. Budnevsky, Yu S. Ivanchuk, Ya S. Shkatova, and R. E. Tokmachev. "COMORBID PATHOLOGY IN PATIENTS WITH BRONCHIAL ASTHMA: LITERATURE REVIEW." NAUKA MOLODYKH (Eruditio Juvenium) 9, no. 1 (March 31, 2021): 136–46. http://dx.doi.org/10.23888/hmj202191136-146.
Full textAbstract:
The article contains a literature review that presents the results of studies of the prevalence of comorbidy in patients with bronchial asthma (BA), as well as the gender- and age-related characteristics of comorbidity in such patients. More than half of asthma patients suffer from the comorbid pathology, which negatively affects the clinical course of asthma, as well as the quality of life. The number of chronic comorbid diseases increases with age, on average to 5 comorbid conditions in BA patients aged 75 years and older. The most common diseases, the prevalence of which increases with age, are cardiovascular, ophthalmological and otolaryngological diseases and diseases of the musculoskeletal system. Female patients with BA, as a rule, are more likely to suffer from comorbid diseases, and on average have more comorbid pathologies than men. The comorbid diseases with the largest gender difference in prevalence are recurrent urinary tract infection, thyroid diseases, migraine and osteoporosis, which are prevalent in women. Among the factors and mechanisms influencing the presence and course of comorbid pathology in asthma patients, there are factors that have an effect before birth and during early childhood, systemic inflammation, hyperinsulinemia, leukotrienes and mitochondrial dysfunction. Despite the vast amount of data, research results are often quite contradictory; further investigations of the mechanisms underlying the relationship between comorbid pathology and asthma are necessary.
43
Boulet, Louis-Philippe, and Michel Laviolette. "Is There a Role for Bronchial Thermoplasty in the Treatment of Asthma?" Canadian Respiratory Journal 19, no. 3 (2012): 191–92. http://dx.doi.org/10.1155/2012/853731.
Full textAbstract:
Bronchial thermoplasty is a new technique proposed to improve control of moderate to severe asthma. It delivers thermal energy to the large airways during a bronchoscopy to decrease the amount of bronchial smooth muscle. This intervention has been shown to reduce asthma exacerbations, and improve asthma control and quality of life over a three-year period without significant complications up to a five-year period. It could be considered as another option in the treatment of selected patients requiring oral and/or high doses of inhaled corticosteroids to control asthma. It should, however, be performed in specialized centres in patients who understand the potential benefits and side-effects of this technique. The response to this treatment varies from one patient to another. Consequently, further studies are required to better define the role of this option in the treatment of asthma.
44
Ścibor, Monika, Andrzej Galbarczyk, and Grazyna Jasienska. "Living Well with Pollution? The Impact of the Concentration of PM2.5 on the Quality of Life of Patients with Asthma." International Journal of Environmental Research and Public Health 16, no. 14 (July 13, 2019): 2502. http://dx.doi.org/10.3390/ijerph16142502.
Full textAbstract:
While the negative influence of environmental pollution on the respiratory system is well established, especially for people with bronchial hyper-reactivity, the impact of particulate matter on quality of life in asthma patients is not well understood. Three hundred adult asthma patients were recruited for a study; for each patient, the daily concentrations of particulate matter of 2.5 µm or less in diameter (PM2.5) were recorded from air quality monitoring stations. The study was conducted over two weeks. After two weeks, the patients filled out the Asthma Quality of Life Questionnaire (AQLQ), evaluating the quality of their lives throughout the monitored period. Patients exposed to a higher concentration of PM2.5 had significantly lower AQLQ scores. Every 10 µg/m3 of an increase in the concentration of PM2.5 resulted in a decrease of the AQLQ score by 0.16. All domains of quality of life (symptoms, activity limitations, emotional functioning, and environmental stimuli) assessed in the questionnaire were negatively affected by PM2.5. These findings provide an important argument in favor of educating physicians and patients and raising awareness about the detrimental health effects of air pollution. Improving the quality of life of people with asthma requires an immediate and substantial reduction of air pollution.
45
França-Pinto, Andrezza, Felipe A. R. Mendes, Regina Maria de Carvalho-Pinto, Rosana Câmara Agondi, Alberto Cukier, Rafael Stelmach, Beatriz M. Saraiva-Romanholo, et al. "Aerobic training decreases bronchial hyperresponsiveness and systemic inflammation in patients with moderate or severe asthma: a randomised controlled trial." Thorax 70, no. 8 (June 10, 2015): 732–39. http://dx.doi.org/10.1136/thoraxjnl-2014-206070.
Full textAbstract:
BackgroundThe benefits of aerobic training for the main features of asthma, such as bronchial hyperresponsiveness (BHR) and inflammation, are poorly understood. We investigated the effects of aerobic training on BHR (primary outcome), serum inflammatory cytokines (secondary outcome), clinical control and asthma quality of life (Asthma Quality of Life Questionnaire (AQLQ)) (tertiary outcomes).MethodsFifty-eight patients were randomly assigned to either the control group (CG) or the aerobic training group (TG). Patients in the CG (educational programme+breathing exercises (sham)) and the TG (same as the CG+aerobic training) were followed for 3 months. BHR, serum cytokine, clinical control, AQLQ, induced sputum and fractional exhaled nitric oxide (FeNO) were evaluated before and after the intervention.ResultsAfter 12 weeks, 43 patients (21 CG/22 TG) completed the study and were analysed. The TG improved in BHR by 1 doubling dose (dd) (95% CI 0.3 to 1.7 dd), and they experienced reduced interleukin 6 (IL-6) and monocyte chemoattractant protein 1 (MCP-1) and improved AQLQ and asthma exacerbation (p<0.05). No effects were seen for IL-5, IL-8, IL-10, sputum cellularity, FeNO or Asthma Control Questionnaire 7 (ACQ-7; p>0.05). A within-group difference was found in the ACQ-6 for patients with non-well-controlled asthma and in sputum eosinophil and FeNO in patients in the TG who had worse airway inflammation.ConclusionsAerobic training reduced BHR and serum proinflammatory cytokines and improved quality of life and asthma exacerbation in patients with moderate or severe asthma. These results suggest that adding exercise as an adjunct therapy to pharmacological treatment could improve the main features of asthma.Trial registration numberNCT02033122.
46
Kryuchkova, A. V., and N. M. Seminina. "Effect of led chromotherapy on the quality of life of patients with bronchial asthma." Science Almanac, no. 1 (2015): 104–9. http://dx.doi.org/10.17117/na.2015.01.104.
Full text
47
Zastrozhina, A. K., I. N. Zakharova, and D. A. Sychev. "Influence of adherence to medical recommendations on symptom control in children with bronchial asthma." Medical Council, no. 11 (July 18, 2019): 160–65. http://dx.doi.org/10.21518/2079-701x-2019-11-160-165.
Full textAbstract:
The search for factors affecting the efficacy of bronchial asthma (BA) therapy in children is an actual problem. subject of many modern scientific studies. Authors note that adherence to therapy in patients with asthma ranges from 30 to 70%. Often this index does not exceed 50%. Analysis of adherence to medical recommendations in children with asthma and the search for compliance reduction factors is one of the ways for optimizing therapy and improving the quality of life for children with asthma.Purpose. In order to optimize bronchial asthma therapy in pediatric practice, we analysed adherence to medical recommendations and its effect on the controllability of the disease in children with asthma.Materials and methods. The study included 94 children aged 6 to 17 years with an established diagnosis of bronchial asthma. All patients had previously been recommended basic therapy in the form of inhaled glucocorticosteroids (ICS) or their fixed combinations with long-acting beta2-adrenomimetikami (LABA). An assessment of BA control symptoms was carried out, and factors affecting adherence to medical recommendations were analyzed. The effect of decreased patient compliance on the control of asthma symptoms was evaluated.Results. 61.7% of children with asthma have insufficient disease control. In 42.55% of patients, a survey revealed insufficient adherence to medical recommendations. 88.3% of children and their parents reported the presence of factors capable of influencing the decrease in compliance. The most frequently occurring factor in reducing adherence to therapy turned out to be insufficient patient awareness of the disease itself, the mechanisms of therapy action, and the prospect of treatment. Statistical data processing showed a statistically significant decrease in adherence to medical recommendations in the group of patients with insufficient asthma symptom control (p = 0.038).Conclusion. Only 38.3% of children had complete asthma symptom control. The statistically significant reduction in adherence to medical recommendations in the group of children with insufficient symptom control suggests the need for educational activities for children with BA and their parents in order to increase adherence to medical recommendations, optimize the effectiveness of therapy and improve the quality of patients’ life.
48
Emel’yanov, A. V., E. V. Leshenkova, and G. R. Sergeyeva. "Mild bronchial asthma: a modern treatment concept." Medical Council, no. 15 (December 8, 2019): 29–36. http://dx.doi.org/10.21518/2079-701x-2019-15-29-36.
Full textAbstract:
Mild bronchial asthma (BA) occurs in 50–75% of patients with this disease. It is characterized by clinical symptoms that are controlled by low doses of inhaled glucocorticoids (IGCS) or anti-leukotriene drugs. Mild BA reduces the quality of life of patients, is accompanied by the development of severe, in some cases fatal exacerbations, and is characterized by a significant cost of treatment. One of the main problems in the management of patients with this disease is their low adherence to IGCS treatment and the excessive use of short-acting 2-adrenomimetic agents. Several clinical studies have shown that the use of a combination of budesonide/formoterol (Symbicort® Turbuhaler®) in an «as needed» mode reduces the incidence of severe exacerbations of mild BA as well as low doses of budesonide, and is characterized by a lower cumulative dose of this glucocorticoid. The results obtained were the basis for the creation of a new treatment concept, which gives preference to the combination of IGCS / formoterol «as needed» in mild BA as a supporting therapy, and for the management of symptoms of the disease.
49
Lemeshko, Valeriya A., Svetlana S. Ratushnyak, Filipp V. Gorkavenko, Evgeniya V. Nazarova, Natalia I. Ilina, and Vitaly V. Omelyanovskiy. "Pharmacoeconomic analysis of bronchial asthma prophylaxis in adults and children with allergic rhinitis by means of sublingual allergen-specific immunotherapy." Russian Journal of Allergy 18, no. 4 (December 14, 2021): 5–17. http://dx.doi.org/10.36691/rja1497.
Full textAbstract:
BACKGROUND: Allergic rhinitis is the most common chronic allergic disease worldwide, and bronchial asthma (BA) is one of the most severe complications of allergic rhinitis. Clinical studies reported that sublingual allergen-specific immunotherapy can reduce the incidence of bronchial asthma in children and adults. However, allergen-specific immunotherapy is rather expensive and is not reimbursed by the state, which transfers the cost of this therapy to patients.
AIMS: To evaluate the cost-effectiveness of allergen-specific immunotherapy in children and adults with allergic rhinitis and/or allergic rhinoconjunctivitis
MATERIALS AND METHODS: The study hypothesized based on study results by Devillier P. et al. in 2019, to which the incidence of asthma was 13.7% and 17.0% in the sublingual allergen-specific immunotherapy + symptomatic therapy and the symptomatic therapy group, respectively (odds ratio: 0.776, 95% confidence interval [0.622; 0.968]). Pharmacoeconomic study based on decision tree model. Costs taken into account are the following: allergen-specific immunotherapy, symptomatic therapy, diagnostics, and routine follow-up visits due to bronchial asthma, outpatient bronchial asthma drug therapy, and hospitalization due to bronchial asthma. The modeling horizon was 5 years, including 2 years of allergen-specific immunotherapy therapy and 3 years of follow-up.
RESULTS: The cost per patient when using allergen-specific immunotherapy in combination with symptomatic therapy was 166,711.93 rubles, whereas with symptomatic therapy was 101,700.35 rubles. The cost-effectiveness ratio for allergen-specific immunotherapy in combination with symptomatic therapy was 193,177.20 rubles per 1 prevented case of asthma, whereas 122,530.55 rubles for symptomatic therapy for 1 prevented case of bronchial asthma. Thus, the cost of 1 averted bronchial asthma case when using allergen-specific immunotherapy in combination with symptomatic therapy is 57.7% higher than with symptomatic therapy. The cost-benefit analysis result revealed that the incremental cost-utility ratio for an additional year of life adjusted for its quality when performing sublingual allergen-specific immunotherapy in combination with symptomatic therapy compared with symptomatic therapy alone in children and adults was 567,365.48 rubles, which is less than the calculated willingness to pay threshold (RUB 2,248,898.50).
CONCLUSIONS: The comparison results of the cost of 1 added quality adjusted life years and willingness to pay threshold concluded that sublingual allergen-specific immunotherapy in combination with symptomatic therapy compared to symptomatic therapy alone is potentially cost-effective in children and adults with allergic rhinitis.
50
Koloskova, О. К., Т. М. Bilous, N. O. Shevchenko, and V. V. Bilous. "FEATURES OF BRONCHIAL ASTHMA CONTROL AND COURSE IN CHILDREN WITH AN ALTERNATIVE ONSET OF THE DISEASE." Eastern Ukrainian Medical Journal 8, no. 4 (2020): 383–92. http://dx.doi.org/10.21272/eumj.2020;8(4):383-392.
Full textAbstract:
Despite the large number of studies on the diagnosis and treatment of asthma and the constant updating of recommendations for the provision of medical care to patients with asthma, this disease still has a significant impact on the quality of life of patients and their families and significant economic losses. However, the peculiarities of bronchial asthma and the diagnosis of certain phenotypes of the disease in children, depending on biomarkers of inflammatory activity in the airways, require greater use of non-invasive diagnostic procedures and optimization of individualized treatment depending on the nature and intensity of inflammation in the respiratory tract.